Abbott
(NYSE: ABT)
boosted its vascular device offerings even more with its acquisition of Cardiovascular Systems this year.
Wondering what comes next? Abbott Vascular President Julie Tyler will explain at our DeviceTalks West event, Oct. 18–19 in Santa Clara. (Register here.)
Even as COVID-19 test sales continue to decline and hammer overall revenue, Abbott officials are betting on a productive, innovative pipeline to build momentum — especially in its medical device business. In a keynote interview on the morning of Oct. 18, Tyler will discuss the company’s product platform, innovation process, and what’s to come after the acquisition of Cardiovascular Systems.
How can the merger with Cardiovascular Systems enable Abbott to better help people with vascular diseases?
